Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer

Ähnliche Einträge

• Real‐world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non‐muscle invasive bladder cancer—Implications for global shortage
  von: Amandeep Arora, et al.
  Veröffentlicht: (2025)
• Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
  von: Arjun Pon Avudaiappan, et al.
  Veröffentlicht: (2024)
• Intravesical gemcitabine and docetaxel vs. re‐induction Bacillus Calmette Guerin as first‐line salvage therapy for non‐muscle invasive bladder cancer
  von: Kylie Yen‐Yi Lim, et al.
  Veröffentlicht: (2025)
• Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia
  von: Alison Hiong, et al.
  Veröffentlicht: (2025)
• Haematuria cancer risk score as a predictor of muscle‐invasive bladder cancer
  von: Serdar Turan, et al.
  Veröffentlicht: (2025)